Vir Biotechnology Presents Phase 3 ECLIPSE 1 Results at AASLD’s Liver Meeting
- Vir Biotechnology to present Phase 3 ECLIPSE 1 results at AASLD’s Liver Meeting in Denver on Nov. 8, 2026.
- The trial evaluates elebsiran with tobevibart for chronic hepatitis delta; the presentation runs from 2:15 to 2:30 p.m. MT.
- Expanded Phase 2 SOLSTICE data presentations are scheduled for Nov. 7-8 during the Nov. 5-9 meeting.
- An investor conference call covering both trials is scheduled for Nov. 9, 2026, at 8:30 a.m. ET / 5:30 a.m. PT.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611051000BIZWIRE_USPR_____20261105_BW268667) on November 05, 2026, and is solely responsible for the information contained therein.